Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5193832
Max Phase: Preclinical
Molecular Formula: C39H44Cl4N6O7S2
Molecular Weight: 914.76
Associated Items:
ID: ALA5193832
Max Phase: Preclinical
Molecular Formula: C39H44Cl4N6O7S2
Molecular Weight: 914.76
Associated Items:
Canonical SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCNC(=O)C(O)C(O)NCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Standard InChI: InChI=1S/C39H44Cl4N6O7S2/c1-48-19-31(29-15-25(40)17-35(42)33(29)21-48)23-5-3-7-27(13-23)57(53,54)46-11-9-44-38(51)37(50)39(52)45-10-12-47-58(55,56)28-8-4-6-24(14-28)32-20-49(2)22-34-30(32)16-26(41)18-36(34)43/h3-8,13-18,31-32,37-38,44,46-47,50-51H,9-12,19-22H2,1-2H3,(H,45,52)/t31-,32-,37?,38?/m0/s1
Standard InChI Key: LZXKISAMAIKCHU-JLTGMVMASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 914.76 | Molecular Weight (Monoisotopic): 912.1467 | AlogP: 4.10 | #Rotatable Bonds: 15 |
Polar Surface Area: 180.41 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.85 | CX Basic pKa: 7.19 | CX LogP: 4.50 | CX LogD: 4.26 |
Aromatic Rings: 4 | Heavy Atoms: 58 | QED Weighted: 0.08 | Np Likeness Score: -0.49 |
1. Jacobs JW, Leadbetter MR, Bell N, Koo-McCoy S, Carreras CW, He L, Kohler J, Kozuka K, Labonté ED, Navre M, Spencer AG, Charmot D.. (2022) Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3., 13 (7.0): [PMID:35859876] [10.1021/acsmedchemlett.2c00037] |
Source(1):